Argos Therapeutics Awarded Patent for Its Experimental Individualized Immunotherapy for the Treatment of HIV Infection
HIV has a high mutation rate resulting in an infected individual carrying a mixture of many different variants. The ability of Argos' strain-independent amplification technology to produce large amounts of the vast array of variants from a small amount of blood or plasma allows the production of individualized immunotherapies matched to each patient's viral 'swarm.' This technology is used to manufacture AGS-004, an experimental immunotherapy for HIV, consisting of optimized dendritic cells electroporated with amplified RNA encoding HIV antigens which include a multitude of strain variants present for selected antigens.
"We are excited that the U.S. Patent and Trademark Office has granted protection for this technology, which provides protection for our ability to customize immune responses to each patient's unique disease variants," said
About the Arcelis® Technology Platform
Arcelis® is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers, and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized cancer immunotherapies. The Arcelis® process uses only a small tumor or blood sample and the patient's own dendritic cells, which are optimized from cells collected by a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease specific antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.
Forward Looking Statements
Any statements in this press release about Argos' future expectations, plans and prospects, including statements about Argos and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including whether Argos' cash resources will be sufficient to fund our continuing operations for the period anticipated; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Argos' product candidates will advance through the clinical trial process on a timely basis and receive approval from the
CONTACT: Media contacts:
Adam DaleyBerry & Company Public Relations 212-253-8881 firstname.lastname@example.org Investor contact: John Menditto Argos Therapeutics, Inc.919-908-0687 email@example.com
News Provided by Acquire Media